Drug in Drug: A host–guest formulation of azocalixarene with hydroxychloroquine for synergistic anti‐inflammation

Shihui Li,Rong Ma,Xin‐Yue Hu,Hua‐Bin Li,Wen‐Chao Geng,Xianglei Kong,Chao Zhang,Dong‐Sheng Guo

DOI: https://doi.org/10.1002/adma.202203765

IF: 29.4

2022-06-12

Advanced Materials

Abstract:Macrocyclic delivery and therapeutics are two significant topics in supramolecular biomedicine. The functional integration of these topics would open new avenues for treating diseases synergistically. However, these two individual topics have been occasionally merged, probably because of the lack of functionalized design of macrocyclic host and the lack of efficient recognition between host and guest drugs. Herein, we proposed a "drug‐in‐drug" strategy in which an active drug is encapsulated by a macrocycle possessing therapeutic activity to form a multi‐functional supramolecular active pharmaceutical ingredient. As a proof‐of‐concept, we prepared a complex of hydroxychloroquine (HCQ) with sulfonated azocalix[4]arene (HCQ@SAC4A) to treat rheumatoid arthritis (RA) combinedly. SAC4A is a therapeutic agent that exhibits scavenging capacity for reactive oxygen species and exerts an anti‐inflammatory effect. It is also a hypoxia‐responsive carrier that could deliver HCQ directly to the inflammatory articular cavity. Consequently, HCQ@SAC4A achieved the synergistic anti‐inflammatory effect on both inflamed RAW 264.7 cells and RA rats. This effect is attributed to the temporal and spatial consistency of the two active ingredients of the complex. As a new paradigm for combinational therapy, the drug‐in‐drug strategy advances in easy preparation, mix‐and‐match combination, and precise ratiometric control. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology